Response to therapy and outcome data according to IDH1 mutant status in total cohort of 1333 patients
| Endpoint . | IDH1 WT (n = 1226) . | IDH1 mutant (n = 107) . | Unadjusted . | Adjusted . | ||
|---|---|---|---|---|---|---|
| OR/HR (95% CI) . | P . | OR/HR (95% CI) . | P . | |||
| Response to therapy | ||||||
| CR/CRi | 83% | 81% | 1.15 (0.68-1.95) | .6 | 0.60 (0.26-1.38) | .2 |
| RD | 10% | 10% | 1.01 (0.52-1.93) | > .999 | 0.72 (0.25-2.09) | .5 |
| ID | 6% | 8% | 1.37 (0.62-3.03) | .4 | 0.53 (0.17-1.65) | .3 |
| Outcome at 10 years | ||||||
| OS | 34% | 34% | 1.07 (0.83-1.36) | .6 | 1.06 (0.79-1.40) | .7 |
| RFS | 34% | 30% | 1.07 (0.82-1.40) | .6 | 1.14 (0.85-1.53) | .4 |
| CIR | 49% | 55% | 1.12 (0.82-1.53) | .5 | 1.13 (0.80-1.58) | .5 |
| CIDCR | 17% | 15% | 0.94 (0.55-1.59) | .8 | 1.14 (0.64-2.05) | .7 |
| Endpoint . | IDH1 WT (n = 1226) . | IDH1 mutant (n = 107) . | Unadjusted . | Adjusted . | ||
|---|---|---|---|---|---|---|
| OR/HR (95% CI) . | P . | OR/HR (95% CI) . | P . | |||
| Response to therapy | ||||||
| CR/CRi | 83% | 81% | 1.15 (0.68-1.95) | .6 | 0.60 (0.26-1.38) | .2 |
| RD | 10% | 10% | 1.01 (0.52-1.93) | > .999 | 0.72 (0.25-2.09) | .5 |
| ID | 6% | 8% | 1.37 (0.62-3.03) | .4 | 0.53 (0.17-1.65) | .3 |
| Outcome at 10 years | ||||||
| OS | 34% | 34% | 1.07 (0.83-1.36) | .6 | 1.06 (0.79-1.40) | .7 |
| RFS | 34% | 30% | 1.07 (0.82-1.40) | .6 | 1.14 (0.85-1.53) | .4 |
| CIR | 49% | 55% | 1.12 (0.82-1.53) | .5 | 1.13 (0.80-1.58) | .5 |
| CIDCR | 17% | 15% | 0.94 (0.55-1.59) | .8 | 1.14 (0.64-2.05) | .7 |
Adjusted analyses were performed using logistic/Cox regression methods adjusted for age, sex, cytogenetic risk group, performance status, de novo/secondary disease, presenting white blood cell count, and FLT3/ITD and NPM1 mutation status.
WT indicates wild-type; OR, odds ratio; HR, hazard ratio; CI, confidence interval; CR, complete remission; CRi, CR with incomplete hematologic recovery; RD, resistant disease; ID, induction death; OS, overall survival; RFS, relapse-free survival; CIR, cumulative incidence of relapse; and CIDCR, cumulative incidence of death in CR